Dinesh Pendharkar

About

Past Chair International Affairs Committee of American Society of Clinical Oncology (ASCO),

Founder Innovative Healthcare Delivery Model-(Cancer care- Pendharkar Model)
Present-Mentor, District Cancer Care Services, Governments of , Madhya Pradesh, Odisha , Himachal Pradesh , Rajasthan Gujarat, Chhattisgarh, Bihar, UP

Director Odisha Cancer Care Foundation

Governing Body Member, Acharya Harihar Post Graduate Institute of Cancer, Cuttack, Odisha


Director Sarvodaya Cancer Institute,Faridabad,Delhi NCR
Consultant Medical Oncology, Asian Cancer Institute , Mumbai
Consultant National Cancer Institute , Tashkent, Uzbekistan
Visiting Professor Andijan State Medical Institute, Uzbekistan
Visiting Professor Khwarezm Branch, Tashkent State Medical Institute
Visiting Professor Salymbekov University , Bishkeke, Kyrgyzstan
Consultant International Cancer Institute, Eldoret ,Kenya

Past Chair Multidisciplinary Cancer Management Course, ASCO.
Member executive committee Asian Cellular Therapy Organisation (ACTO)
Past Visiting professor State Medical University of Armenia.
Past President Indian Society of Oncology,ISO
Past President Indian Society of Medical and Paediatric Oncology ,ISMPO

One of the First Practitioners in cancer chemotherapy in India. Has many publications including international recognized practice changing research in “ management of hand foot syndrome”.
Partnering and advisor to multiple countries and organisations in oncology care, education.

Employment

• Sarvodaya Cancer Institute Director
  2017 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (10)

• Haplotype Considerations for Sickle Cell Gene Therapy
  Blood Global Hematology 2026 DOI: 10.1016/j.bglo.2026.100143
  +Save
• Hemoglobin A2 levels in Indian patients with sickle cell disease reveal heterozygosity
  Blood Global Hematology 2026 DOI: 10.1016/j.bglo.2025.100059
  +Save
• Tracing the origin of sickle cell disease back to 50 000 years
  Blood Global Hematology 2026 DOI: 10.1016/j.bglo.2025.100041
  +Save
• Sickle Cell Disease in Burundi- An unexplored terrain?
  2023 DOI: 10.22541/au.168724268.85144365/v1
  +Save
• Real-world HbF status in sickle cell disease from an endemic zone.
  2022 DOI: 10.22541/au.166661823.32397322/v1
  +Save
• Cancer care for the poor-health system augmentation model.
  Journal of Clinical Oncology 2022 DOI: 10.1200/jco.2022.40.16_suppl.e13514
  +Save
• Feasibility of next generation sequencing (NGS) from Uzbekistan: A preliminary data analysis.
  Journal of Clinical Oncology 2022 DOI: 10.1200/jco.2022.40.16_suppl.e14579
  +Save
• Cancer care system strengthening (Pendharkar model) offers uninterrupted care continuum during COVID19 pandemic.
  Journal of Clinical Oncology 2021 DOI: 10.1200/jco.2021.39.15_suppl.e13540
  +Save
• Making the Best Use of Resources in Global Cancer Care.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2020 DOI: 10.1200/edbk_290311
  +Save
• Thinking Differently in Global Health in Oncology Using a Diagonal Approach: Harnessing Similarities, Improving Education, and Empowering an Alternative Oncology Workforce
  American Society of Clinical Oncology Educational Book 2017 DOI: 10.1200/edbk_175246
  +Save